🔎 Trials Near Me

ホーム › 急性骨髄性白血病

米国で参加者を募集している急性骨髄性白血病の臨床試験

米国全土の拠点で、急性骨髄性白血病に関する276件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07581002

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

被験者募集中第2相
60歳以上 · 全性別 · 2026/10/02更新 · NCT07437950

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07304011

Assessment of Geriatric Evaluations Impact on New AML Guidance

被験者募集中観察研究
50歳以上 · 全性別 · 2026/10/02更新 · NCT05909501

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT06904066

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07723703

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06763341

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06548230

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

被験者募集中第3相
12歳以上 · 全性別 · 2026/09/25更新 · NCT07211958

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03874052

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

被験者募集中早期第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06398457

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03661307

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06871410

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

被験者募集中第1/2相健康なボランティア歓迎
12歳以上 · 全性別 · 2026/09/23更新 · NCT05360160

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

被験者募集中第1相
21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

A Study of CRD3874-SI in People With Leukemia

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07661095

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。